ASAida Smajlović

Aida Smajlović

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aida Smajlović has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases

    by Nahida Srabović, Monika Rustemović Čorbić, Esmeralda Dautović, Aida Smajlović, Adaleta Softić, Anida Delimehić, Jasmina Grapkić Aličić, Damir Terzić, Emina Hodžić, Arnela Šakušić Mujić, et al.

    Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting glucose (FG) and hemoglobin A1c (HbA1c) in CVD patients. Methods: The case–control study included 123 patients from Tuzla Canton, Bosnia, and Herzegovina, with a diagnosis of CVD, treated in three health centers: Public Health Center Gračanica, Banovići, and Čelić. Of total patients, 84 were statin users (39 atorvastatin users and 45 rosuvastatin users) and 39 were not. Demographic data, diagnosis, and data of the therapy were taken from the medical records, as well as data of the FG and HbA1c, measured before or within 3 months of the statin therapy introduction. For the same patients, FG and HbA1c were also measured at least 3 months after the introduction of therapy. Results: Obtained results have shown a significant increase of FG in CVD patients on statin therapy in relation to control (p = 0.034). Comparing the diabetogenic effects of atrovastatin and rosuvastatin, it was found that the HbA1c in patients on atorvastatin therapy was significantly higher comparing to those on rosuvastatain therapy (p = 0.028). The FG was significantly increased (p = 0.027) after atrovastatin therapy. Similar results were obtained in diabetogenic CVD patients, where HbA1c on atorvastatin therapy was significantly higher comparing to HbA1c in those on rosuvastatain therapy (p = 0.039). A significant correlation was found between the increase in FG and HbA1c with the duration of atorvastatin therapy (p = 0.001 and p = 0.033), and between the increase in HbA1c and the duration of rosuvastatin therapy (p = 0.001). Conclusion: Long-term therapy with high-potency statins, atorvastatin, and rosuvastatin, may increase levels of FG and HbA1c in patients with CVD, where atorvastatin shows more significant effects.

  • Open Access

    In vitro release and stability assessment of Origanum compactum liposomal dispersion with antifungal activity

    by Merima Ibišević, Ivana Nešić, Saša Pilipović, Aida Smajlović, Nahida Srabović, Vesna Nikolić, Dragan Cvetković, Ermina Cilović Kozarević, Emir Horozić, Enida Karić, et al.

    Origanum compactum, an endemic Moroccan medicinal herb, possesses many different activities such as antibacterial, antifungal, antioxidant and anticancer. The aim of this study was to investigate the stability and antifungal activity of liposomal dispersion with this essential oil. Liposomal dispersion stability was evaluated by testing the vesicle size, polydispersity index and zeta potential. It was also examined the in vitro release of thymol and carvacrol from liposomal dispersion. The major components of this essential oil were carvacrol (58.4%), thymol (12.5%) and γ-terpinene (10.7%). Origanum compactum essential oil showed a strong antifungal activity, and the inhibition zones ranged from 24 to 45 mm. After 210 minutes, 80.88% thymol and 16.67% carvacrol were released. Stability assessment was performed for three months and the liposomal dispersion showed a good stability.


  • Open Access

    Valuation of Antioxidative, Antimicrobial and Cytotoxic Activity of the Synthetized Arylmethylenbis (3-Hydroxy-5,5-Dimethyl-2- Cyclohexen-1-One) Derivatives

    by Amra Dzabic, S. Muratović, E. Veljović, A. Softić, E. Dautović, M. Šljivić Husejnović, E. Horozić, A. Smajlović

    Arylmethylenebis(3-hydroxy-5,5-dimethyl-2-cyclohexen-1-one) derivatives (aryl=2-hydroxynaphthyl (1) and 3,4-dihydroxyphenyl (2) have been synthesized and their structures have been elucidated. Both compounds were examined for their antioxidant, antimicrobial and cytotoxic activity. Antioxidative activities of synthesized compounds were evaluated by 2,2-diphenyl-1-picryl-hydrazyl (DPPH) and ferric reducing antioxidant power (FRAP) methods. The microbial screening was performed by diffusion method on bacterial strains Staphylococcus aureus, Enterococcus faecalis, Bacillus subtilis and Candida albicans. Cytotoxic activity was tested on liver hepatocellular carcinoma cell line (Hep G2) by Neutral red assay. Compared to compound 2, compound 1 showed better antimicrobial and antifungal activity, while compound 2 showed better antioxidant activity with IC50 of 0.0156 mM and FRAP value 50469.44 µmol/l Fe2+. Both compounds showed cytotoxic activity. Obtained results implicate the importance of arylmethylenebis(3-hydroxy-5,5-dimethyl-2-cyclohexen-1-on) derivatives as a potential antioxidant, antimicrobial and cytotoxic agents.